Leadiant Biosciences, Inc., is researching and providing medicines to help people affected by specific rare diseases, including carnitine deficiency, cystinosis, Hodgkin disease and invasive fungal infections.
Carnitine deficiency is a rare metabolic disorder that prevents the body from processing certain fats into energy, particularly during fasting. The primary form of the disorder strikes an estimated one in every 50,000 to one in every 100,000 newborns in the U.S.
Cystinosis is a rare metabolic disease in which an amino acid called cystine accumulates and forms crystals that can damage many organs and tissues, especially the eyes and kidneys. Cystinosis is thought to affect about 2,000 people worldwide, including approximately 500 people in the U.S.
Hodgkin disease, also known as Hodgkin lymphoma, is a cancer of the immune system characterized by the presence of a type of cell called the Reed-Sternberg cell. An estimated 8,500 new cases of Hodgkin disease are diagnosed in the U.S. each year.
Invasive fungal infections
Invasive fungal infections are those that result when fungi invade and establish themselves within the deep tissues, causing prolonged illnesses often characterized by fever. These infections can involve any part of the body and are common – and especially deadly – in individuals with compromised immune systems.